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EDITORIAL
Epigenetics and Orofacial Clefts: A Brief Introduction
Gemma C. Sharp, Ph.D., Evie Stergiakouli, Ph.D., Jonathan Sandy, Ph.D., F.Med.Sci., Caroline Relton, Ph.D.
The term ‘‘epigenetics’’ is used liberally as a possible
explanation for traits and conditions that do not appear to
be solely genetic in origin. Since orofacial clefts (OFCs) fall
into that large category, it is not surprising that the scientiﬁc
literature in this area has also pointed to a potential
etiologic role for epigenetics (Dixon et al., 2011).
WHAT IS EPIGENETICS?
Whereas genetic inﬂuences on our traits involve variation
in our DNA sequence, epigenetic inﬂuences involve changes
in how DNA is packaged, expressed, and turned into
protein. The underlying DNA remains the same, but
chemical modiﬁcations change levels of gene activity. These
modiﬁcations can attach to the DNA itself or to the histone
proteins theDNA iswrapped around. InDNAmethylation,
which is the most commonly studied epigenetic mechanism,
methyl groups attach to DNA andmay inﬂuence expression
of nearby genes—often switching them off.
Although every cell in every tissue has essentially the
same DNA sequence, epigenetic processes differ between
cells. They play a large role in cellular differentiation by
enabling a cell to express only the genes that are necessary
for its function. Epigenetic modiﬁcations can last for the
whole of a cell’s life and survive division, but they can also
change in response to external inﬂuences. Together, this
means that environmental factors might trigger long-term
changes in gene activity, which in turn might inﬂuence
health and disease over an individual’s life (Godfrey et al.,
2011). Some evidence also suggests that epigenetic modi-
ﬁcations to gamete DNA might enable these traits to be
passed to the next generation. Although most of the DNA
is stripped of methylation in early development, experi-
ments have shown that marks can remain on certain parts
of the DNA that cause aberrant methylation patterns to be
reestablished during development (Greer et al., 2014).
Another way in which epigenetics can be passed between
generations is during pregnancy, when a mother’s environ-
ment can inﬂuence the epigenome (all of the epigenetic
modiﬁcations in the genome) of her developing baby in
utero.
IS EPIGENETICS RELEVANT TO OROFACIAL CLEFTS?
Epigenetic processes, particularly DNAmethylation, are
important in determining the structure and function of the
developing embryonic tissues, so it is plausible that aberrant
epigenetic mechanisms may contribute to OFCs. Although
human evidence is lacking, evidence from mouse models
suggests an important role for DNAmethylation and other
epigenetic processes in orofacial development and OFCs
(Kuriyama et al., 2008; Seelan et al., 2013; Juriloff et al.,
2014).
Additionally, in humans, large observational epigenome-
wide studies and meta-analyses have found consistent
associations between putative risk factors for OFCs and
differential methylation in DNA of babies of exposed
mothers. For example, maternal obesity (Sharp et al., 2015)
and folate deﬁciency (Joubert et al., 2016a) have been
linked to changes in themethylation of neonatal cord blood
DNA. Through its role as a coenzyme of one-carbon
metabolism, folate is directly involved in methyl group
transfer in DNA methylation, which might support
evidence for folate deﬁciency and impaired folate metab-
olism as risk factors for OFCs. Prenatal tobacco smoke
exposure has a particularly large effect on offspring DNA
methylation. A recent meta-analysis of epigenome-wide
association studies from 13 cohorts (n¼6685) identiﬁed
more than 6000 sites near 3620 genes thatwere differentially
methylated in relation to maternal smoking (Joubert et al.,
2016b). Twenty-seven of these genes have previously been
linked to OFCs, including VAX1, NOG, BMP4, and
MSX1. This suggests that maternal smoking may inﬂuence
offspring risk of OFC through a mechanism involving
DNA methylation.
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Although we are unaware of any studies investigating
this, it seems plausible that epigenetic modiﬁcations
associated with the development of OFCs could also
directly inﬂuence longer-term outcomes; that is, the
downstream consequences of having an OFC may be
mediated by changes to the epigenome, and these changes
may be independent of the factors that caused the OFC
(Fig. 1). Observational studies have found associations
between early-life exposures and differential methylation
that persists in later life (Simpkin et al., 2015) as well as
associations between early-life methylation and later-life
OFC-associated outcomes, such as cancer (Verma, 2012).
WHAT ARE THE IMPLICATIONS OF EPIGENETICS FOR
CLINICAL PRACTICE?
As technologies to measure epigenetic phenomena
become less expensive, and the statistical tools to analyze
these become more reﬁned, the potential to use epigenetic
analysis in the clinic is increasing. In linewith this, twomain
clinical applications are emerging: (1) development of
epigenetic biomarkers to predict or classify disease and (2)
exploitation of epigenetic mechanisms to prevent or treat
disease.
EPIGENETIC BIOMARKERS FOR PREDICTION OR
CLASSIFICATION
Most notably in cancer research, aberrant DNA
methylation is being explored as a biomarker of tumor
progression for both diagnosis and prognosis (Delpu et al.,
2013). One advantage of an epigenetic biomarker over a
genetic one is that aberrant methylation is more common
than genetic mutation. However, the unique features of
epigenetic processes also present challenges in developing
accurate biomarkers: (1) some epigenetic changes are cell-
speciﬁc andmay not be detectable in diagnostic tissues such
as blood; (2) some epigenetic changes are reversible, so the
timing of measurement is important; and (3) epigenetic
changes can occur in response to a wide range of
environmental factors and are inﬂuenced by the underlying
genetic sequence, so factors such as age, sex, diet, smoking,
and genotype may affect biomarker efﬁcacy. Nevertheless,
epigenetic biomarkers are showing some success as
predictive tools, and it is possible that such tools may be
useful in predicting or classifying OFCs or downstream
consequences of OFCs. For example, if a biomarker can be
measured in an accessible tissue, such as amniotic ﬂuid,
maternal blood, or chorionic villus blood, it might be a
useful tool for antenatal diagnosis or classiﬁcation of
OFCs. Additionally, if measured at birth or early
childhood, a biomarker might be useful in predicting
surgical success, likelihood of scarring, or longer-term
health outcomes, thus identifying groups of patients who
might beneﬁt from extra monitoring.
EPIGENETIC MECHANISMS FOR TREATMENT OR PREVENTION
Epigenetic studies in relevant tissue, such as lip/palate
tissue collected during cleft surgery, can be combined with
causal inference techniques to offer valuable insights into
causation of disease and therefore biological mechanisms.
Ultimately, this will help to inform intervention and
prevention. As mentioned previously, epigenetic changes
are reversible and can be inﬂuenced by external factors.
Thus, disease-causing epigenetic mechanisms could poten-
tially be manipulated to treat or prevent disease. For
example, demethylating agents have shown some success in
cancer chemotherapy, and there are current efforts to
develop drugs that target epigenetic changes in speciﬁc
genes (Stein, 2014). If epigenetic mechanisms are shown to
have a strong causal role inOFCs, then developing prenatal
therapies to alter or halt epigenetic changesmay be effective
in reducing incidence.
SUMMARY
It is biologically plausible that epigenetic changes might
be involved in the development of OFCs and in OFC
outcomes. Despite this, there has been very little investiga-
tion of such changes in humans. This presents exciting and
promising opportunities for further research that could
inform better prediction, prevention, and management
strategies for clinical use.
FIGURE 1 Potential pathways through which epigenetics might inﬂuence development of orofacial clefts and cleft-associated outcomes.
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